MP20-02 Aquablation at 4-years: the largest, real world, single-center study and longest follow-up data for this innovative BPH treatment

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology I (MP20)1 May 2024MP20-02 Aquablation at 4-years: the largest, real world, single-center study and longest follow-up data for this innovative BPH treatment Olamide O. Omidele, Alexandra R. Siegal, and Steven A. Kaplan Olamide O. OmideleOlamide O. Omidele , Alexandra R. SiegalAlexandra R. Siegal , and Steven A. KaplanSteven A. Kaplan View All Author Informationhttps://doi.org/10.1097/01.JU.0001008732.80104.31.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Aquablation utilizes ultrasound-guided, robot-assisted water jet technology to ablate prostatic tissue with the goal of preserving sexual function while reducing operative time. The objective of this study is to assess 4-year safety and efficacy outcomes in a real-world experience of the Aquablation procedure for the treatment of men with symptomatic BPH in all volume prostate glands. METHODS: A prospective assessment of 265 men with moderate-to-severe BPH symptoms who underwent robotic-assisted Aquablation procedure at a single academic center was performed. The study period was between December 2019 and October 2023. Demographics, age, prostate volume, history of prior intervention, IPSS score before and after Aquablation treatment, urinary flow rate, outcomes, and complications were recorded. RESULTS: In this cohort of 265 men, mean prostatic volume was 106.3 mL (range 38-293 mL). Of note, 22 (8.9%) men had previous prostate artery embolization, 9 (3.4%) prostatic urethral lift, and 7 (2.6%) water thermotherapy. Of the 265 men, 111 (41.9%) with a mean prostate volume of 111.3 cc were in urinary retention. Of those, 108 (97.3%) were able to void without a catheter. At one-year, mean prostate volume reduction was 41.1 mL (-38.7%). Patient symptoms showed a significant improvement from an initial mean IPSS of 24.2 (SD 7.8) decreasing to 5.1 (SD 2.1) at 4 years (Table 1). Mean peak urinary flow rate (Qmax) also demonstrated improvement and increased from 6.4 (SD 4.3) to 16.9 (SD 7.8) mL/sec during the study period. Persistent post-operative urgency at>3 months occurred in 17 men (16.4%) who required either antimuscarinic or beta – 3 agonist medication. Postoperative antegrade ejaculation was preserved in 99% of men. Complications included 6 men (2.3%) requiring blood transfusion, 17 (6.4%) with a postoperative urinary tract infection, and 1 (0.4%) having a bladder neck disruption. 5 men (1.8%) required surgical retreatment during the study period. CONCLUSIONS: In the largest real world, prospective database experience with the longest follow up on the Aquablation procedure, we demonstrate it to be safe with both durable subjective and objective outcomes at 4 years and preservation of antegrade ejaculation similar to previous registration data. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e319 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Olamide O. Omidele More articles by this author Alexandra R. Siegal More articles by this author Steven A. Kaplan More articles by this author Expand All Advertisement PDF downloadLoading ...